Arvinas to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Arvinas (Nasdaq: ARVN) said management will participate in two investor conferences in November 2025: Guggenheim’s 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 and the Jefferies London Healthcare Conference on Tuesday, November 18, 2025.

Both presentations will offer a live audio webcast accessible via links and the company’s Events and Presentations web section.

News Market Reaction – ARVN

-4.14%

1 alert

-4.14% News Effect

On the day this news was published, ARVN declined 4.14%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences.

• Guggenheim’s 2^nd Annual Healthcare Innovation Conference on Tuesday, November 11. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
• Jefferies London Healthcare Conference on Tuesday, November 18. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
  
  

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X. 

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

FAQ

When will Arvinas (ARVN) present at the Guggenheim Healthcare Innovation Conference?

Arvinas will present on Tuesday, November 11, 2025 with a live audio webcast available.

When will Arvinas (ARVN) present at the Jefferies London Healthcare Conference?

Arvinas will present on Tuesday, November 18, 2025 with a live audio webcast available.

Where can investors access Arvinas (ARVN) conference webcasts for November 2025?

Live audio webcasts will be available via the provided conference links and the company’s Events and Presentations webpage.

What topics will Arvinas (ARVN) management cover at the November 2025 conferences?

The announcement states management will present recent developments and outlook; specific slide topics were not disclosed.

Will Arvinas (ARVN) provide replay access to the November 2025 conference presentations?

The announcement confirms live audio webcasts; it directs investors to the Events and Presentations page for access but does not detail replay timing.